JPMorgan Chase & Co. Reiterates €110.00 Price Target for MorphoSys (MOR)
MorphoSys (ETR:MOR) received a €110.00 ($127.91) target price from JPMorgan Chase & Co. in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 7.32% from the stock’s current price.
MOR has been the topic of a number of other reports. Commerzbank set a €107.00 ($124.42) target price on shares of MorphoSys and gave the stock a “neutral” rating in a report on Wednesday, August 22nd. Royal Bank of Canada set a €65.00 ($75.58) target price on shares of MorphoSys and gave the stock a “sell” rating in a report on Monday, October 1st. Deutsche Bank set a €120.00 ($139.53) target price on shares of MorphoSys and gave the stock a “neutral” rating in a report on Monday, August 6th. Oddo Bhf set a €110.00 ($127.91) target price on shares of MorphoSys and gave the stock a “buy” rating in a report on Thursday, October 11th. Finally, HSBC set a €56.00 ($65.12) target price on shares of MorphoSys and gave the stock a “sell” rating in a report on Tuesday, August 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of €96.40 ($112.09).
MorphoSys stock opened at €102.50 ($119.19) on Wednesday. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: What does earnings per share mean?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.